Man Group PLC Ocular Therapeutix, Inc Transaction History

Man Group PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.85 - $10.93 $82,940 - $235,464	21,543 New	21,543 $196,000
Q3 2023 Nov 14, 2023	BUY	$3.14 - $5.04 $50,261 - $80,675	16,007 New	16,007 $50,000
Q1 2022 May 16, 2022	SELL	$4.83 - $7.35 $516,665 - $786,229	-106,970 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$6.16 - $12.07 $658,935 - $1.29 Million	106,970 New	106,970 $746,000
Q1 2020 May 15, 2020	SELL	$3.95 - $7.4 $3 Million - $5.63 Million	-760,490 Closed	0 $0
Q4 2019 Feb 18, 2020	SELL	$2.57 - $4.73 $2.95 Million - $5.43 Million	-1,148,988 Reduced 60.17%	760,490 $3 Million
Q3 2019 Nov 14, 2019	SELL	$3.04 - $5.32 $755,959 - $1.32 Million	-248,671 Reduced 11.52%	1,909,478 $5.81 Million
Q2 2019 Aug 14, 2019	BUY	$2.46 - $4.52 $1.07 Million - $1.96 Million	434,693 Added 25.22%	2,158,149 $9.5 Million
Q1 2019 May 15, 2019	BUY	$3.51 - $4.77 $1.88 Million - $2.56 Million	535,948 Added 45.13%	1,723,456 $6.84 Million
Q4 2018 Feb 14, 2019	BUY	$3.87 - $7.11 $2.65 Million - $4.87 Million	684,391 Added 136.03%	1,187,508 $4.73 Million
Q3 2018 Nov 14, 2018	BUY	$5.42 - $6.99 $2.73 Million - $3.52 Million	503,117 New	503,117 $3.46 Million

171

138M

150K

225K

Ticker OCUL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,966,896
Market Cap $654M
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.